Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Mäkelä E, Pavic K, Varila T, Salmenniemi U, Löyttyniemi E, Nagelli SG, Ammunét T, Kähäri VM, Clark RE, Elo LL, Bachanaboyina VK, Lucas CM, Itälä-Remes M, Westermarck J. Mäkelä E, et al. Among authors: salmenniemi u. Clin Cancer Res. 2021 May 15;27(10):2848-2860. doi: 10.1158/1078-0432.CCR-20-3679. Epub 2021 Mar 5. Clin Cancer Res. 2021. PMID: 33674272
Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT.
Nagler A, Ngoya M, Galimard JE, Labopin M, Kröger N, Socié G, Gedde-Dahl T, Potter V, Schroeder T, Platzbecker U, Ganser A, Blaise D, Salmenniemi U, Maertens J, Craddock C, Labussière-Wallet H, Yakoub-Agha I, Savani B, Mohty M. Nagler A, et al. Among authors: salmenniemi u. Bone Marrow Transplant. 2022 Dec;57(12):1856. doi: 10.1038/s41409-022-01853-w. Bone Marrow Transplant. 2022. PMID: 36280759 No abstract available.
Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT.
Giebel S, Labopin M, Socié G, Aljurf M, Salmenniemi U, Labussière-Wallet H, Srour M, Kröger N, Zahrani MA, Lioure B, Reményi P, Arat M, Bourhis JH, Helbig G, Tbakhi A, Forcade E, Huynh A, Brissot E, Spirydonidis A, Savani BN, Peric Z, Nagler A, Mohty M. Giebel S, et al. Among authors: salmenniemi u. Bone Marrow Transplant. 2023 May;58(5):506-513. doi: 10.1038/s41409-023-01917-5. Epub 2023 Feb 1. Bone Marrow Transplant. 2023. PMID: 36725978
Good responses but high TRM in adult patients after MSC therapy for GvHD.
Salmenniemi U, Itälä-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, Korhonen M. Salmenniemi U, et al. Bone Marrow Transplant. 2017 Apr;52(4):606-608. doi: 10.1038/bmt.2016.317. Epub 2016 Dec 12. Bone Marrow Transplant. 2017. PMID: 27941780 Clinical Trial. No abstract available.
Treatment of adult acute myeloid leukemia.
Järvenpää J, Itälä-Remes M, Kauko T, Salmenniemi U, Kauppila M, Putkonen M, Salmi T, Remes K. Järvenpää J, et al. Among authors: salmenniemi u. Duodecim. 2016;132(16):1465-73. Duodecim. 2016. PMID: 29188934
Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety.
Keto J, Kaartinen T, Salmenniemi U, Castrén J, Partanen J, Hänninen A, Korhonen M, Lähteenmäki K, Itälä-Remes M, Nystedt J. Keto J, et al. Among authors: salmenniemi u. Mol Ther Methods Clin Dev. 2018 Feb 8;9:109-118. doi: 10.1016/j.omtm.2018.02.001. eCollection 2018 Jun 15. Mol Ther Methods Clin Dev. 2018. PMID: 29516024 Free PMC article.
104 results